CVC Welcomes Apollo as Minority Investor in Syntegon

An investor group led by Apollo-managed funds is acquiring a 37% minority stake in Syntegon from CVC. As a globally leading technology company, Syntegon is a strategic partner for the entire lifecycle of the pharmaceutical, biotechnology and food industries. Record revenue of EUR 1.75 billion in 2025 and a 27% year-on-year increase in EBITDA to EUR 282 million underscore Syntegon’s operational strength in highly regulated markets. With fully integrated line solutions along the entire value chain, a portfolio of approximately 2,000 patents and patent applications and groundbreaking innovations, Syntegon has established itself as the technological leader in the industry. One example is SynTiso, the world’s first gloveless high-speed filling line for liquid pharmaceuticals.

Throughout the partnership with CVC, Syntegon has successfully transformed and established itself globally as an independent, strong brand. Through a consistent strategic focus on the service business as well as on the pharma and biotech sectors, the company has quadrupled its profitability since 2019. Key drivers were accelerated organic growth, strengthened competitiveness through modernization and the establishment of new plants, as well as targeted M&A activities. These include the acquisition of Telstar (2024) to strengthen the pharma liquid segment and the acquisition of a majority stake in Klenzaids (2023) to expand in the Asian market.

In the next growth phase, Syntegon aims to gain further share in mission-critical and largely non-cyclical growing end markets. A focus is on the expansion in the USA, where Apollo’s strong expertise will provide new momentum. In addition, the enormous service potential of the world’s largest installed system base is to be systematically unlocked. Employees, customers and partners, benefit from continuity and ongoing investments in development and service. Under the existing management, Syntegon continues to operate from its headquarters in Stuttgart and will consistently build its profitable growth trajectory. The transaction is subject to customary regulatory approvals. The parties have agreed to maintain confidentiality regarding the financial details of the agreement.